Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
No rate change, no EMI shock : RBI’s move to keep housing demand on track
2/10/2025
12 equity funds outperform with over 30% returns since last Dussehra
2/10/2025
3 largecap mutual funds beat category average and benchmark in one year
2/10/2025
South Korean shares hit record as chipmakers surge on OpenAI deal
2/10/2025
Miners, gold stocks power Australian shares higher ; Wall Street gains add lift
2/10/2025
Goldman Sachs' Rs 10,000 crore India portfolio : 4 stocks rally 50-155% in 1 year
2/10/2025
